Place your bets for Pona's next indication...
Listed below are potential new indications for Ponatinib based on published pre-clinical data and current IST's.
Indication (target) / % Mutation / WW Annual Pts. w/Mutation
1. AML (FLT-3) / 30% / 4,130
2. GIST (KIT/PDGFR) / 90% / 50,800
3. Endometrial (FGFR2)/ 30% / 159,900
4. SCC (FGFR1) / 21% / 101,400
5. MTC (RET) / 72% / 4,600
6. Bladder (FGFR3) / 50% / 191,500
7. Breast (FGFR1/2) / 14% / 193,200
8. NSCLC (RET+FGFR1/2)/ 3.5% / 22,500
9. GBM (VEGFR) / 40% / 60,000
10. Gastric (FGFR2) / 4.1% / 40,550
In my opinion we will see two of these trials start this year. I think a survey is called for here, no?
In case you are wondering....if you add up these patients and assume 30% for 2nd line use, and then another 30% for market share, and yearly cost of treatment of $100K...you get annual sales of $7.45B...just sayin'...
Vive Le Clusig!
